Sumitomo Pharma America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
- Conditions
- Chronic Lymphocytic LeukemiaSLLSmall Lymphocytic LymphomaCLL
- Interventions
- Combination Product: TP-0903 and ibrutinib combination therapy
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03572634
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Duke University, Durham, North Carolina, United States
A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
- Conditions
- Bipolar 1 DepressionDepressive Episode
- Interventions
- Drug: SEP-4199 400 mgDrug: PlaceboDrug: SEP-4199 200 mg
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 344
- Registration Number
- NCT03543410
- Locations
- 🇷🇸
Clinical Center "Dr. Dragisa Misovic-Dedinje", Belgrade, Serbia
🇸🇰Crystal Comfort s.r.o. Psychiatricka ambulancia, Vranov nad Toplou, Slovakia
🇷🇸Special Hospital for Psychiatric Diseases "Kovin", Kovin, Serbia
A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03525405
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03429218
- Locations
- 🇺🇸
University of Texas Southwestern UTSW, Dallas, Texas, United States
🇺🇸Massachusetts General Hospital MGH, Boston, Massachusetts, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT03416816
- Locations
- 🇺🇸
Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Karmos Cancer Center, Detroit, Michigan, United States
🇺🇸UT Heatlh San Antonio, San Antonio, Texas, United States
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03416335
- Locations
- 🇺🇸
Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸M.D. Anderson Cancer Center, The University of Texas, Houston, Texas, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers
- Conditions
- Drug-drug Interactions
- Interventions
- Drug: cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03411122
- Locations
- 🇺🇸
Accel Research Sites, DeLand, Florida, United States
A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
- Conditions
- Motor OFF Episodes Associated With Parkinson's Disease
- Interventions
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT03391882
- Locations
- 🇮🇹
IRCCS San Raffaele Pisana-Clinical Trial Center, Rome, Italy
🇦🇹Wilhelminenspital, Department of Neurology, Vienna, Austria
🇩🇪Klinik Haag i.OB, Haag In Oberbayern, Germany
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
- Conditions
- Renal Cell Carcinoma (RCC)Urothelial CarcinomaPrimary Peritoneal CancerSerous Epithelial Ovarian CancerFallopian Tube CancerPlatinum-resistant Ovarian Cancer (PROC)
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03311334
- Locations
- 🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03298984
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Columbia University, New York, New York, United States